「ros」の検索結果

Resolves GWAS associations to candidate causal variants and credible sets via SuSiE, susie_rss, FINEMAP, CAVIAR, DAP-G, PAINTOR, PolyFun, SuSiEx, MultiSuSiE, and FOCUS. Use when narrowing a GWAS lead SNP to a 95 percent credible set, choosing between in-sample and reference LD, calibrating non-sparse loci with SuSiE-inf or FINEMAP-inf, integrating functional priors via PolyFun, fine-mapping across ancestries with SuSiEx, diagnosing LD mismatch via estimate_s_rss and kriging_rss, handling HLA or long-range LD, or feeding credible sets into coloc.susie for colocalization.

日本語の概要は準備中です。原文の説明を表示しています。

Fits structural equation models to GWAS summary statistics using GenomicSEM (Grotzinger 2019), including common-factor models, confirmatory factor models, ESEM, common-factor GWAS with Q_SNP heterogeneity, multivariate Wald tests, and stratified GenomicSEM partitioned heritability. Reconciles results against MTAG multi-trait analysis. Handles sample overlap via the LDSC sampling-covariance matrix, identifies and resolves Heywood cases, and verifies model fit with CFI / RMSEA. Use when modeling latent genetic architecture across correlated traits, running multivariate GWAS on a shared factor, distinguishing factor-mediated from trait-specific SNP effects, or comparing GenomicSEM common-factor results against MTAG when both depend on accurate sampling covariance.

日本語の概要は準備中です。原文の説明を表示しています。

Assesses ChIP-seq quality across antibody specificity, fragmentation, enrichment, replicate concordance, and library complexity. Computes FRiP, NSC/RSC (phantompeakqualtools), library complexity (NRF/PBC1/PBC2), deepTools plotFingerprint (JS distance, AUC, synthetic JS), ChIPQC, IDR with ENCODE Nself/Nt rules, and detects hyper-ChIPable artifacts. Use when validating an antibody, diagnosing failed peak calls, deciding whether to proceed with downstream analysis, grading against ENCODE thresholds, or auditing replicate concordance.

日本語の概要は準備中です。原文の説明を表示しています。

Builds and applies 3D pharmacophore models using RDKit Pharm3D, the apo2ph4 receptor-based workflow (Heider et al 2022/2023 J Chem Inf Model 63:147-158), Pharmer / Pharmit (search), and PharmacoForge (diffusion-based generation, Flynn et al 2025 Front Bioinform), covering ligand-based pharmacophore (from active set alignment) and receptor-based pharmacophore (from binding pocket geometry). Explicit handling of feature types, geometric tolerances, partial matching, and pharmacophore-based virtual screening. Use when identifying scaffold-hopping candidates, building shape-and-feature search queries, or transferring SAR across chemotypes.

日本語の概要は準備中です。原文の説明を表示しています。

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

日本語の概要は準備中です。原文の説明を表示しています。

Standardizes molecular structures using ChEMBL chembl_structure_pipeline and RDKit rdMolStandardize covering sanitization, salt/solvent stripping, neutralization, tautomer canonicalization, stereochemistry standardization, mixture handling, and isotope normalization. Explicitly compares ChEMBL pipeline, canSARchem, and PubChem standardization choices. Use when preparing libraries for QSAR training, joining datasets across sources, deduplicating compound collections, or building canonical compound registries.

日本語の概要は準備中です。原文の説明を表示しています。

Performs ML-based protein-ligand pose prediction and scoring using DiffDock-L (diffusion-based), Boltz-1 / Boltz-2 (foundation model with affinity), Chai-1, AlphaFold3 ligand, EquiBind, TANKBind, NeuralPLexer, and hybrid workflows (DiffDock pose + GNINA rescore + PoseBusters QC). Explicit handling of when ML beats classical docking, when classical beats ML, the PB-invalid pose problem, and rescoring as the standard production hybrid. Use when modern docking is needed: foundation-model ligand-pose prediction, AI rescoring of classical poses, or scaffold-hopping in cross-docking scenarios.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Designs PROTACs, molecular glues, and bivalent degraders with explicit handling of E3 ligase choice (VHL, CRBN, IAP, MDM2, KEAP1), linker design (length, composition, rigidity), ternary complex prediction (PRosettaC, DeepTernary, AlphaFold3 with constraints), cooperativity (alpha), DC50 / Dmax characterization, hook effect, and prediction-experiment reconciliation. Use when designing targeted protein degraders, planning linker SAR, predicting ternary complex stability, or building generative degrader workflows.

日本語の概要は準備中です。原文の説明を表示しています。

Build a differential-ready consensus peakset from per-replicate ATAC-seq peaks using iterative overlap removal, fixed-width re-centering, and majority-rule overlap. Use when generating a stable peak coordinate system for downstream differential accessibility, ML feature engineering, cross-sample comparison, or fixed-width peak counts; covers Corces 2018 iterative overlap (501 bp), DiffBind summit re-centering, and ENCODE consistency rules.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies alternative splicing as PSI (percent spliced in) from RNA-seq using rMATS-turbo (BAM-based event), SUPPA2 (TPM-based event), MAJIQ V3 (LSV-based Bayesian), leafcutter (annotation-free intron clusters), VAST-TOOLS (cross-species with microexon support), Shiba (junction-imbalance-corrected, 2025 SOTA at low coverage), or IRFinder-S (intron retention coverage-aware). Distinguishes the five canonical event classes (SE, A5SS, A3SS, MXE, RI), special classes (microexons, exitrons, AFE/ALE), intron retention subtypes (canonical RI vs detained introns), and applies effective-length normalization. Use when measuring splice-site usage or isoform inclusion ratios from short-read RNA-seq.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze TF motif accessibility variability across samples or single cells using chromVAR. Use when identifying TF motifs whose accessibility correlates with conditions, computing per-sample motif z-scores after matched background correction, comparing to ArchR / Signac equivalents, or distinguishing motif-accessibility signal from per-site footprinting.

日本語の概要は準備中です。原文の説明を表示しています。

Identify differentially accessible chromatin regions across conditions using DiffBind, csaw, DESeq2, or edgeR. Use when comparing ATAC-seq accessibility between treatment groups, choosing between consensus-peak vs sliding-window approaches, picking the correct normalization (full library vs reads-in-peaks), correcting batch with SVA/RUVseq, or interpreting log2FC and FDR thresholds in a chromatin context.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about the financial differences between being an owner-operator vs company driver — gross pay, expenses, net pay, capital requirements, risk tolerance, lifestyle, and how to evaluate the path. Reference industry pay surveys.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks the cost of pulling a Motor Vehicle Record (MVR) in a specific state, or wants to compare MVR fees across multiple states, or is budgeting annual compliance costs for a multi-state fleet. Reference the canonical fee table below; flag that fees change (re-verify with state DMV before annual budget planning).

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about the FMCSA Drug & Alcohol Clearinghouse — full vs limited query, pre-employment vs annual query, query credit purchasing, who has access (employers, drivers, MROs, SAPs, state licensing agencies), reporting violations to the Clearinghouse, the "prohibited" status workflow, consent forms, or how to register/use the clearinghouse.fmcsa.dot.gov portal. Cite 49 CFR 382.701-727.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a driver has been disqualified or is at risk of disqualification — major offense convictions (DUI, leaving the scene, drug trafficking with CMV), serious traffic violations, RR-grade-crossing violations, imminent-hazard out-of-service, or Clearinghouse positive-test prohibited status. Also use when planning a return-to-duty pathway, SAP process, or reinstatement timeline. Covers 49 CFR 383.51, Part 40 Subpart O, and Part 391.15.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a dispatcher, operations manager, or owner asks how to plan loads to minimize empty (deadhead) miles, sequence freight efficiently, balance regional capacity, design dedicated loops, or build a load-pairing strategy across customers. Covers loaded-ratio math, lane balance, region-pair pricing, and software-supported optimization.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks anything that touches US Department of Transportation (DOT) or Federal Motor Carrier Safety Administration (FMCSA) regulation for commercial motor vehicles (CMVs) — including who's regulated, MC vs DOT number differences, operating authority, BOC-3 process agents, MCS-150 biennial updates, intrastate vs interstate distinctions, exemptions, or pointing to the right CFR section. Cite the actual regulation when answering. Don't guess; if you're not sure which Part applies, ask the user to clarify the operation type (for-hire vs private, passenger vs property, intra vs interstate, hazmat, gross weight rating).

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks about driver fatigue management — circadian rhythm impact on driving, recognizing fatigue, fatigue risk management programs (FRMS), night driving safety, microsleep recognition, drowsiness detection technology, and how HOS rules relate to actual fatigue (and why 11-hour driving is risky even when legal). Reference FMCSA Fatigue Management research.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill to understand why CSA BASIC alert thresholds differ across carrier types. Covers general freight (65th percentile), passenger/hazmat (60th), and the regulatory rationale.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user asks how to market a trucking company — sales channels, prospecting, website + brand, industry directories (D&B Hoovers, ZoomInfo), referral programs, content marketing, and ROI of different acquisition channels. Reference industry sales practices.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill to explain to customers/sales prospects why FMCSA CSA scores are not available in real-time. Covers the SAFER refresh cycle and what 'real-time' actually means for CSA data.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze a Coval audio-quality testing report from runs across different voice, speaking-style, volume, interruption, and background-noise scenarios. Use when a user provides a Coval report URL, report export, run IDs, screenshots, or metric summary and wants evidence-backed next steps such as prompt changes, tool handling fixes, STT/TTS adjustments, trace setup, or expanded audio-scenario coverage.

日本語の概要は準備中です。原文の説明を表示しています。